

RESEARCH

Open Access



Exosomes derived from platelet-rich plasma administration in site mediate cartilage protection in subtalar osteoarthritis

Yu Zhang^{1†}, Xiaowei Wang^{1†}, Jian Chen^{1†}, Dingfei Qian^{1,2†}, Peng Gao^{1†}, Tao Qin¹, Tao Jiang¹, Jiang Yi¹, Tao Xu¹, Yifan Huang¹, Qian Wang¹, Zheng Zhou¹, Tianyi Bao¹, Xuan Zhao¹, Hao Liu¹, Ziyang Zheng¹, Jin Fan¹, Shujie Zhao^{1*}, Qingqing Li^{1*} and Guoyong Yin^{1*} 

Abstract

Subtalar osteoarthritis (STOA) is often secondary to chronic ankle sprains, which seriously affects the quality of life of patients. Due to its etiology and pathogenesis was not studied equivocally yet, there is currently a lack of effective conservative treatments. Although they have been used for tissue repair, platelet-rich plasma-derived exosomes (PRP-Exo) have the disadvantage of low retention and short-lived therapeutic effects. This study aimed to determine whether incorporation of PRP-Exo in thermosensitive hydrogel (Gel) increased their retention in the joint and thereby playing a therapeutic role on STOA due to chronic mechanical instability established by transecting lateral ligaments (anterior talofibular ligament (ATFL)/calcaneal fibular ligament (CFL)). PRP-Exo incorporated Gel (Exo-Gel) system, composed of Poloxamer-407 and 188 mixture-based thermoresponsive hydrogel matrix in an optimal ratio, was determined by its release ability of Exo and rheology of Gel response to different temperature. The biological activity of Exo-Gel was evaluated in vitro, and the therapeutic effect of Exo-Gel on STOA was evaluated in vivo. Exo released from Exo-Gel continuously for 28 days could promote the proliferation and migration of mouse bone mesenchymal stem cells (mBMSCs) and chondrocytes, at the same time enhance the chondrogenic differentiation of mBMSCs, and inhibit inflammation-induced chondrocyte degeneration. In vivo experiments confirmed that Exo-Gel increased the local retention of Exo, inhibited the apoptosis and hypertrophy of chondrocytes, enhanced their proliferation, and potentially played the role in stem cell recruitment to delay the development of STOA. Thus, Delivery of PRP-Exo incorporated in thermosensitive Gel provides a novel approach of cell-free therapy and has therapeutic effect on STOA.

Keywords: Subtalar osteoarthritis, Platelet-rich plasma, Exosome, In situ drug delivery


*Correspondence: zhaoshujie@njmu.edu.cn; liqingqing_1999@163.com; guoyong_yin@sina.com

[†]Yu Zhang, Xiaowei Wang, Jian Chen, Dingfei Qian and Peng Gao contributed equally

¹ Department of Orthopedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu, China

Full list of author information is available at the end of the article





Introduction

Ankle sprain is the most common injury related to physical activity and athletic participation, accounting for about 60% of all injuries in interscholastic sports [1, 2]. The annual medical cost of approximately 2 million acute ankle sprains is estimated to be approximately \$ 4.2 billion [3, 4]. Therefore, it is a major public health problem and a major health care burden, although ankle sprain is often regarded as an inconsequential injury. Unfortunately, ankle sprain is not a onetime injury, which is one of the strongest risk factors for recurrent ankle sprain and chronic ankle instability (CAI) [3, 4]. More importantly, as many as 78% of CAI patients develop posttraumatic ankle osteoarthritis (OA) [5, 6]. In addition, lateral ankle sprain is the most common sprain injury, contributed to 13–22% of ankle OA cases and 80% of posttraumatic OA cases [7]. At present, the focus of attention has been on the talocrural joint degeneration caused by lateral ankle sprains. However, due to the similar trauma mechanisms and clinical manifestations of subtalar joint, it leads to underdiagnosis or misdiagnosis of anklesubtalar joint complex injury [8]. To resolve these problems, pathophysiology of ankle OA should be elucidated first. Unlike a major breakthrough in molecular pathophysiological

research in knee OA due to the establishment of surgically induced mouse knee OA models in 2005 [9–11], only a few of studies [12, 13] have reported that mechanical instability could be induced in the ankle joint in this mouse model by removal of anterior talofibular ligament (ATFL)/calcaneal fibular ligament (CFL) on its lateral side, to provide a reliable animal model of subtalar OA (STOA). Although such studies substantially promote the development of ankle joint research, the molecular mechanisms of cartilage homeostasis in subtalar joint and intervention for acute lateral ankle sprains are still rarely studied.

Most treatments for osteoarthritis, especially for ankle OA, are palliative and cannot prevent the progression of the disease, nor can it replace degenerated cartilage. At present, there is an urgent need for an effective conservative treatment method that can not only maintain joint function but also relieve pain, so as to improve the quality of life of patients. Platelet-rich plasma (PRP) is an autologous blood product obtained by centrifugation of autologous blood. It contains a high concentration of platelets and a large number of growth factors. Various growth factors and cytokines are released from degranulated platelets and play a vital role in joint homeostasis

and healing [14]. In recent years, intraarticular injection of PRP has become a treatment option for knee [15–17] and ankle [18, 19] OA. Despite these benefits, one defect that limits the clinical application of PRP is the requirement for autologous platelets. In addition to these growth factors, stimulation of platelets can also cause them to secrete a large number of extracellular vesicles, including exosomes (Exo, 40–100 nm in diameter) [20]. In the past few decades, the discovery of Exo is one of the most revolutionary contributions to cell biology [21]. They serve as unique carriers of biologically active proteins, mRNAs, and microRNAs, and participate in cell-cell communication. Importantly, recent studies have found that PRP-derived Exo (PRP-Exo) have great potential in the field of tissue repair and regeneration [22, 23], with antiinflammatory effect and positive regulation of cell biological activity [24]. In addition, Exo have the ability to carry large cargo loads to protect the contents, such as transforming growth factor (TGF) β 1, platelet-derived growth factor (PDGF) BB, vascular endothelial growth factor (VEGF), stromal cell-derived factor (SDF)-1, also known as CXCL12 [24]. Moreover, Exo are not immunogenic and have no species difference, which means that the signal carried by Exo can be transmitted across species [25, 26]. Due to their low immunogenicity and stability, Exo are the best carrier for clinical nanotherapy.

Considering this immediate washout of Exo, which will lead to a reduction in therapeutic exposure, scholars have conducted indepth studies on the use of injectable hydrogels (Gel) to increase the retention of therapeutic drugs [27–29]. Incorporation of Exo in Gel can allow the controlled release of Exo for a longer period of time, which can even further increase the therapeutic exposure and maximize their efficacy. Injectable Gel based on synthetic materials (such as e.g., poly (ethylene glycol) (PEG) or poly (*N*-isopropylacrylamide)-based)) are easily tunable, and have controllable biochemical properties. Besides, they may be less susceptible to batch-to-batch variations and the most promising candidate systems to increase the local retention of Exo [27, 30]. Previously, a thermoresponsive in situ gel drug delivery system was developed with biosafety poloxamers (Poloxamers 407 and 188) [31], nonionic amphiphilic copolymers composed of a central hydrophobic block of polyoxypropylene (PPO) flanked by two hydrophilic blocks of polyoxyethylene (PEO). Two hydrophilic polyethylene oxides (PEO) [31, 32]. The thermoresponsive property of Gel can be attributed to the phase reverse thermal gelation of the poloxamers under certain condition. However, whether PRP-Exo combined with thermosensitive Gel can prolong Exo retention and enhance therapeutic effects is unknown.

Here, we investigated the use of thermosensitive Gel with poloxamers as a platform for PRP-Exo delivery, aiming to prolong local delivery of Exo to targeted organs. In this study, PRP-Exo incorporated Gel (Exo-Gel) prolonged the release of Exo with biological activity, which promoted the proliferation and migration of mouse bone mesenchymal stem cells (mBMSCs) and chondrocytes, enhanced the chondrogenic differentiation of mBMSCs, and protected chondrocytes against apoptosis and degeneration induced by inflammation in vitro. In lateral ankle instability mouse model after transecting ATFL/CFL, compared with Exo alone, Exo-Gel increased the retention of exosomes in the ankle, and therefore improved the therapeutic effect in STOA probably via homing induction of endogenous mBMSCs to the injury site, inducing chondrogenic differentiation, and reducing inflammation-induced cartilage damage.

Materials and methods

Reagents and antibodies

The mBMSC culture and differentiation medium was purchased from Cyagen (China). The chondrocyte activator IL-1 β was purchased from Sigma-Aldrich (USA). The primary antibodies used in this study included mouse anti-CD9, CD63, CD81, and SOX9 (Santa Cruz Biotechnology, USA); rabbit anti-COL II (Santa Cruz Biotechnology); rabbit anti-PDGFBB, VEGF, SDF-1, COL X, anti-cleaved caspase-3, Bcl-2, Bax, and GAPDH (Abcam, USA); rabbit anti-TGF β 1, Smad2/3, p-Smad2/3, EKRI/2, p-EKRI/2, p38, and p-p38 (Cell Signaling Technology, USA); rabbit anti- COL X and Ki67 (Novus, USA); rabbit anti-Aggregan, and MMP13 (Proteintech; China). The secondary antibodies used in this study included Alexa-488 conjugated-goat anti-rabbit IgG (H+L) (Jackson ImmunoResearch, USA); horseradish peroxidase-conjugated-goat anti-rabbit IgG (H+L) and horseradish peroxidase-conjugated-goat anti-Mouse IgG (H+L) (Invitrogen, USA); Nuclei was stained with DAPI dihydrochloride (Thermo Fisher Scientific, USA). Flow cytometry analysis was performed to identify the characterization of mBMSCs stained with FITC-conjugated or PE-conjugated anti-mouse CD44, CD45, CD90, and CD105 (BD, USA).

Animals

All mice in this study were acquired from Gempharmatech (China). 6–8 weeks old male C57/B6 mice were used for STOA model. 3 w-old mice were used for BMSCs isolation, and newborn pups at postnatal 1 d were used for chondrocytes isolation. All experimental procedures were conducted in conformity with institutional guidelines for the care and use of laboratory animals and protocols, which were approved by the Animal Care and Use

Committee of Affiliated Drum Tower Hospital, Medical School of Nanjing University (No. YKK1760).

Cell culture of mBMSCs

BMSCs were obtained from bone marrow in 3 week-old C57/B6 male mice, and seeded in T25 cell culture flasks with 6 ml BMSC culture medium at 37 °C. The cells (P0) were passaged when they fused at 80%. These reseeded cells were considered to be the first generation (P1), and so on as the second (P2), third (P3), etc. The BMSC culture medium was refreshed every 3 days, and P3 cells were used in followup experiments.

Cell culture of chondrocytes

To extract chondrocytes, 1 d-old pups were sacrificed for collection of cartilage from knees. First, cartilage was into small pieces after washing with PBS. Second, the samples were digested in 0.25% trypsin-EDTA (Gibco, USA) solution for 5 min, and DMEM-F12 (Gibco) containing 10% collagenase type II (Sigma-Aldrich) for 6 h at 37 °C, successively. The released chondrocytes were seeded in T25 cell culture flasks. Cells were passaged at a ratio of 1:3 at 80% confluence. The culture medium was refreshed every 3 days.

Identification of BMSCs

The morphology of P0 and P3 mBMSCs was observed via microscopy (Nikon TS2, Japan). Flow cytometry cytoflex (Beckman, USA) was used to detect the surface markers of mBMSCs (CD44, CD45, CD90, and CD105). The data was analyzed by Flowjo 7.6 (TreeStar, USA). Adipogenic, Osteogenic, and chondrogenic differentiation of mBMSCs were performed according to standard culture methods, and measured via Oil red O staining, Alizarin Red staining, and Alcian blue (AB) staining, respectively. These images were obtained through bright-field microscope (Nikon TS2, Japan).

Chondrogenic differentiation of mBMSCs

According to the instructions, induction medium (Cytogen, China; containing: TGFβ3 1 mg per 100 ml medium) of chondrogenic differentiation was replaced every 3 days. TGFβ1 neutralizing antibody (1 μg/ml, BD) was administrated in chondrogenic differentiation process. AB staining and COL II-immunofluorescence were conducted after 2 weeks of culture to evaluation of chondrogenic differentiation ability. These results were observed through microscope (Nikon TS2) and Cell imager (Bio-tek Cytation1, USA), respectively.

PRP extraction

Based on the methods of Tao et al. [23] and Guo et al. [22], whole blood samples were collected from healthy

volunteers and placed with acid-citrate Dextrose solution A (ACD-A) in anticoagulant tubes (1 ml ACD-A/9 ml blood). After centrifugation at 160 g for 10 min, platelet-containing plasma was carefully absorbed and transferred to a new centrifuge tube (Beckman coulter, USA) and centrifuged again at 250 g for 15 min. The supernatant plasma was discarded, before the platelet pellet was resuspended in the residual plasma to obtain 4 ml PRP.

Isolation of PRP-Exo

According to the methods of Torreggiani et al. [20], PRP samples were centrifuged at 250 g for 15 min to obtain PRP microspheres and the platelet pellet was washed with PBS (Ca²⁺-free and Mg²⁺-free, Gibco). After activating 4 ml PRP suspension with 1 ml of 10% CaCl₂ and 1000 U thrombin (Hunan Yige Pharmaceutical, China), the suspension was centrifuged in series at low speeds (300 g for 10 min, 2000 g for 10 min) to discard cell debris. Then, the supernatant was filtered through a 0.22 μm filter (Millipore, Germany), and the filtrate was transferred to a 15 ml ultrafiltration centrifuge tube (Millipore) under 4000 g centrifugation for 50 min. The liquid was washed with PBS and ultrafiltered at 4000 g again. To purify the Exo, the medium was added onto a 30% sucrose/D₂O cushion in an Ultra-Clear™ tube (Beckman Coulter, USA) and ultra-centrifuged at 100,000 g for 70 min. After washing by PBS, Exo suspension was ultracentrifuged again at the same high speed for 70 min. The Exo were then carefully resuspended in sterile PBS and stored at - 80 °C for subsequent experiments.

Identification of PRP-Exo

Nanosight tracking analysis (NTA; Nanosight, UK) was used to measure the concentration and size distribution of Exo. Transmission electron microscopy (TEM; Tecnai 12, Philips, The Netherlands) was used to identify the morphology of Exo after incorporated in Gel. The biosignature proteins of PRP-Exo, consisting of CD81, CD9, CD63, Tgfβ1, PDGFBB, VEGF, and SDF-1 were determined by western blotting assays.

Gel and Exo-Gel preparation

The production methods of Gel have been described in our previous report [33], the total polymer concentration of blank Gel was set to 22.9% (w/w), of which the concentration of Poloxamer 407 (PEO₁₀₁-PPO₆₆-PEO₁₀₁, Sigma-Aldrich) and 188 (PEO₈₀-PPO₂₇-PEO₈₀, Aladdin, China) was fixed at 17.9% (w/w) and 5% (w/w), respectively. Poloxamer 407 and 188 were added into ddH₂O according to the ratio to stir and mix evenly at 4 °C. Then, the Gel in liquid state was fully mixed with extracted Exo, and this Exo incorporated Gel (Exo-Gel) system was freeze-dried by lyophilizer (Christ Alpha1-2, Germany).




Fig. 1 Characterization of PRP-Exo and Exo-Gel. **A** Morphology of Exo examined by TEM. Scale bar: 200 nm. **B** Particle size distribution of Exo measured by NTA. **C** Western blotting analysis of the surface biomarkers CD9, CD63, and CD81 on Exo, and the encapsulated proteins TGFβ1, PDGFBB, VEGF, and SDF-1, as compared with APP. **D** Photographs of Exo-Gel demonstrated the thermoresponsiveness of the formulation, for which the polymer solution at room temperature (25 °C) reversibly transformed into a hydrogel at 37 °C. **E** SEM of the morphology of Exo loaded in Gel (bar = 500 nm). **F** Exo release profiles from Gel at 25 and 37 °C. **G** Thermoresponsive release profile of Exo loaded in Gel detected by Bradford Protein Assay at different time-points. Error bars represent the means ± SEM (n = 3). **H** Particle size distribution of Exo released from Gel measured by NTA. **I** In vitro setup to determine uptake of DiR-labeled Exo released from Gel at 48 h by mBMSCs and chondrocytes. **J** Fluorescent images of mBMSCs and chondrocytes cocultured with Exo-Gel showing that Exo could be taken up by mBMSCs and chondrocytes after release from Gel

After that, it was further detected by SEM (Philips). Liquid Gel was transferred to transwell inserts with 8 μm pore size (Millipore) and solidified by raising temperature to 37.0 $^{\circ}\text{C}$ in the cell incubator. The conditioned medium from Exo-Gel (200 μg Exo incorporated in 100 μl thermosensitive Gel) incubation for 1 week was obtained by placing the transwell inserts in wells containing 1 ml of medium, and used to coculture with mBMSCs and chondrocytes for multiple functional tests, such as proliferation, migration, differentiation, and apoptosis.

Thermoresponsive release profile of Exo-Gel

For release studies, the same amount of Exo-Gel was placed into transwell inserts as described above and incubated in medium at 25 and 37 $^{\circ}\text{C}$. The supernatant was removed and fresh medium was added at different time-points. The number of Exo released into the medium was determined using the Bradford Protein Assay Kit (Beyotime, China) and the size distribution of Exo at 2d postincubation was detected by NTA (Nanosight).

Uptake of Exo by mBMSCs and chondrocytes

For the fluorescent labeling of Exo, DiR-solution (Eugene, USA) was added to PBS and incubated as manufacturer instructed, then centrifuged 100,000 g at 4 $^{\circ}\text{C}$ for 1 h to remove excess dye. These DiR-labeled Exo incorporated Gel (200 $\mu\text{g}/100 \mu\text{l}$) placed in a transwell insert and cocultured with mBMSCs and chondrocytes in the bottom well for 48 h. Cells were washed with PBS thrice, fixed in 4% paraformaldehyde (PFA), and permeabilized with 0.05% Triton X-100 for 5 min, followed by incubation with FITC Phalloidine (Yeasen, China). Nuclei was stained with DAPI dihydrochloride. Fluorescent images were photographed by Cell imager (Bio-tek Cytation1).

Cell Counting Kit-8 analysis

Viability of mBMSCs and chondrocytes was evaluated with a Cell Counting Kit-8 (CCK-8) assay (Dojindo, Japan). After 0, 12 h, 1 d, and 2 d, the wells were washed with PBS thrice, and CCK8 solution (10 μl ; 1:10 dilution) in fresh culture medium was added to wells and incubated for 2 h at 37 $^{\circ}\text{C}$. The absorbance was measured at 450 nm with a microplate reader (ELx800, Bio-tek). The cell growth curve is drawn according to the measured OD value.

5-Ethynyl-2'-deoxyuridine (EDU) analysis

Cell proliferation was evaluated using an EDU kit (RiboBio, China) in accordance with the manufacturer's protocol. Briefly, mBMSCs and chondrocytes were seeded into 24-well plates 20,000 per well and incubated with EDU medium for 2 h. After washing with PBS, the cells were fixed in 4% PFA and permeabilized with 0.05% Triton X-100 for 5 min. At last, we added staining solution to each well followed by incubating at room temperature for 30 min. Nuclei was stained by Hoechst 33,342 and the images were taken under Cell imager (Bio-tek Cytation1).

Migration assay

Transwell assay was used to analyze the migration ability of BMSCs and chondrocytes under different treatments. Briefly, 20,000 cells were seeded into the upper chamber of a 24-well transwell plate (Millipore; pore size: 8 μm) after which 600 $\mu\text{L}/\text{well}$ medium treated differently were added to the lower chamber. Following incubation for 24 h, cells that migrated to the lower surface of the filter membrane were stained with 0.5% Crystal Violet for 30 min and observed by microscopy (Nikon TS2). Migratory activity was assessed by counting the number of cells.

A scratch wound assay was also performed to evaluate cell migration capability. In brief, cells were cultured in 6-well plates to 100% confluence. We used a sterile 200 μl pipette tip to scrape the cell layer. After washing with PBS, the images of each processing groups were recorded at 0 and 24 h after scratching by microscopy (Nikon TS2).

Real-time quantitative PCR

Total RNA was extracted from the mBMSCs using the RNA-Quick Purification Kit (Vazyme, China) and the cDNA was amplified using the HiScript II Q RT Super-Mix for qPCR (Vazyme) according to the manufacturer's instructions. The qPCR was performed with SYBR Green PCR Master Mix (Vazyme) on using ABI steponeplus real-time PCR system (Applied Biosystems, USA). The level of expression was standardized to GAPDH, and the relative expression level was evaluated using the $2^{-\Delta\Delta\text{CT}}$ approach. The primers used in this experiment were synthesized by GENEbay (China) with the following sequence: GAPDH (Forward: 5'-TCATGGGTGTGA ACC ATGAGAA-3', Reverse: 5'-GGCATGGACTGT

(See figure on next page.)

Fig. 2 Exo-Gel promoted proliferation and migration of mBMSCs in vitro. **A** In vitro setup to determine if Exo released from Exo-Gel maintain their ability in proliferation and migration of mBMSCs. **B** The cell viability of mBMSCs cocultured with conditioned medium examined by CCK-8 analysis. Data are expressed as means \pm SEM (n = 6). *p < 0.05, Exo-Gel group compared to Gel group. **C** Proliferation of mBMSCs was confirmed by EDU kit assay (bar = 100 μm). **D** Quantification of rate of EDU positive cells in **C** was performed. Data are expressed as means \pm SEM (n = 8). **E** Transwell assay to show a representative image of migrating mBMSCs (bar = 200 μm). **F** Quantitative analysis of migrating cells in **E**. Data are expressed as means \pm SEM (n = 6). **G** A representative image showing the migration ability of mBMSCs by the scratch test (bar = 500 μm). **H** Quantitative analysis of mBMSC migration rate (**G**). Data are expressed as means \pm SEM (n = 6). *p < 0.05




Fig. 2 (See legend on previous page.)

GGTCATG AG-3'), COL II (Forward: 5'-CACACTGGT AAGTGGGGCAAGACCG-3', Reverse: 5'-GGATTG TGTGTTTC AGGGTTCGGG-3'), ACAN (Forward: 5'-CCTGCTACTTCATCGACCCC-3', Reverse: 5'-AGA TGCTGTTGACTCGAACCT-3'), and SOX9 (Forward: 5'-GGTGC T CAAGGGCTACGACT-3', Reverse: 5'-GGGTGGTCTTTCTTGTGCTG-3').

Chondrocyte apoptosis by flow cytometry

Chondrocyte apoptosis were assessed using an Annexin V-FITC/PI apoptosis detection kit (Keygen Biotech, China). According to the manufacturer's protocol, the chondrocytes were digested by 0.25% trypsin without EDTA, washed with PBS and centrifuged at 300g for 5 min. The collected cells (500,000/per tube) were resuspended in binding buffer (500 μ l) containing 5 μ l Annexin V-FITC and 5 μ l Propidium Iodide (PI) after 10 min incubation in dark and detected by flow cytometer (Beckman, USA).

Cell fluorescence analysis

Cells were fixed with 4% PFA for 20 min, washed with PBS three times, permeabilized with 0.05% Triton X-100 for 10 min and blocked with 10% goat serum for 2 h. Then, samples were incubated with primary antibodies overnight at 4°C, followed by Alexa-488 conjugated-goat secondary antibody (Jackson ImmunoResearch) for 2 h at room temperature. After triple washing by PBS, nuclei were stained with DAPI and fluorescent images were acquired using fluorescence microscope (Leica DMI3000B, Germany) and Cell imager (Bio-tek Cytation1).

Western blot assay

Total protein was purified from cells by RIPA lysis (Keygen Biotech, China). Protein concentration was quantified by Bradford Protein Assay Kit (Beyotime). Equal amounts of protein were separated by SDS-PAGE, and transferred to PVDF membranes (Millipore). Subsequently, PVDF membrane was blocked by 5% bovine


serum albumin for 2 h at room temperature prior to incubating overnight at 4°C in respective primary antibodies. Membranes were then incubated for 2 h at room temperature with the appropriate secondary antibodies. The bands were exposed by applying chemiluminescence kit (Beyotime) in an imaging system (Bio-Rad, USA). Quantification of band intensity was also performed by ImageJ (National Institutes of Health, USA).

Animal experiments

C57 male mice aged 6–8 weeks were used to performed chronic ankle instability model by transecting lateral ligaments (ATFL/CFL) as previously described [12, 13]. Under anesthetic conditions, CFL, connecting from the apex of the fibular malleolus to the lateral surface of the calcaneus, and ATFL, running from the distal anterior tip of the fibula to the lateral talar neck were both excised at its attachment sites. The lateral ankle capsule, which connects from anterior aspects of fibula to the lateral side of the talus, was incised after removal of CFL and ATFL. After surgery, 2 μ l PBS, 2 μ l blank Gel, 2 μ l PBS containing 2 μ g Exo, or 2 μ l Exo-Gel (4 μ g Exo/2 μ l Gel) were respectively injected into subtalar joint, and consequently depending on the composition of the injection, the mice were assigned to below groups: PBS, Gel, Exo, or Exo-Gel (n = 6/group). A sham operation was performed on the opposite ankle using the same skin incision without ligament/tendon resection. To identify sustained-release of Gel, DiR-labeled Exo (4 μ g/2 μ l PBS) and Exo-Gel (4 μ g/2 μ l) were locally injected into subtalar joints via precooled Hamilton precision syringe (Hamilton Co., Ltd, Switzerland), respectively, and the IVIS Spectrum imaging system (PerkinElmer, USA) was used to observe right subtalar joints on 3, 7, 14, and 28 d after surgery. A sham operation was performed on the opposite ankle using the same skin incision without ligament/tendon resection. The entire operation was finished after the suture of the incision. Mice were allowed to move freely in the cages and had free access to food and water. The mice were sacrificed at 4 and 8 weeks after the surgery.

(See figure on next page.)

Fig. 3 Exo-Gel enhanced chondrogenic differentiation mBMSCs in vitro. **A** In vitro estimate the ability of Exo-Gel by coculture in chondrogenic differentiation of mBMSCs. **B** RT-PCR analysis for COL II, ACAN and SOX9 mRNA in mBMSCs treated as described in (A) at different time-points. Data are represented as means \pm SEM (n = 3). **C** AB staining of mBMSCs in different treatment groups under light microscopy on the 14th day of induction of differentiation (bar = 100 μ m). **D** Immunofluorescent assay of mBMSCs for COL II (red) and DAPI (Blue) in different treatment groups at the same time-point in **C** (bar = 100 μ m). **E** Western blot assay to detect the protein expression levels of COL II, ACAN and SOX9 at the same time-point in **C**. **F** Quantification of protein expression in **E**. GAPDH was used as loading control. Data are expressed as means \pm SEM (n = 3). **G** Representative Western blot showing the levels of total protein and phosphorylated protein for the indicated molecules (Smad2/3, ERK1/2, and p38) in mBMSCs with or without TGF β 1 neutralizing antibody at the same time-point in **C**. **H** Quantification of protein expression and the level of signaling activation in **G**. GAPDH was used as loading control. Data are expressed as means \pm SEM (n = 3). **I** AB staining of mBMSCs with or without TGF β 1 neutralizing antibody under light microscopy on the 14th day of differentiation (bar = 100 μ m). **J** Immunofluorescent assay of mBMSCs for COL II (red) and DAPI (blue) under the same condition as (I) (bar = 100 μ m). *p < 0.05



Histomorphological detection

Ankle samples at 8 weeks postinjury were fixed in 4% PFA, decalcified in EDTA, and embedded in paraffin. Five- μm frontal sections were prepared and stained with safranin O and fast green, HE, toluidine blue (TB), and alcian blue (AB), respectively, according to the standard protocol, and the morphology of the tissue was observed by microscopy (Nikon TS2, Japan).

Immunohistochemical analysis

Ankle samples at 4 weeks postinjury were prepared according to standard dewaxing procedure. The slices were soaked in citric acid buffer (10mM citric acid, pH 6.0) at 100 °C for 10min to display antigens and 3% hydrogen peroxide was added for 10min to inactivate endogenous peroxidase. Then, immunohistochemical staining was performed using a previously reported protocol. After incubation with the primary antibodies at 4 °C overnight, the slides were subsequently stained with horseradish peroxidase-conjugated secondary antibody (Invitrogen). The presence of antigen in cartilage was determined by counting the number of positively stained chondrocytes by microscopy (Nikon TS2).

TUNEL staining

TUNEL (Roche, Switzerland) staining of cells and tissue slides was performed in dark for 30min at 37 °C based on the manufacturer's protocol. Nuclei was stained with DAPI. Images were captured by using Cell imager (Biotek Cytation1).

Statistical analysis

GraphPad 7.0 and SPSS 19.0 software were used to process and analyze the data. All independent experiments were performed in triplicate and all quantitative data were expressed means \pm SEM. Data were analyzed using the Student's T-test or one-way or two-way ANOVA to determine statistical differences. A value of $p < 0.05$ was considered as statistically significant.

Results

Characterization of PRP-Exo

In order to fully characterize the purified PRP nanoparticles, transmission electron microscopy (TEM), nano visual tracking analysis (NTA) and western blotting were

used. TEM shows that the diameter of round nanoparticles is between 40 and 100nm, which is consistent with the literature report [20] (Fig. 1A). The particle size distribution of NTA is similar (Fig. 1B), indicating the existence of Exo. In addition, western blotting (Fig. 1C) showed that PRP-Exo-specific exosomal surface markers CD9, CD63, and CD81 were positive, further confirming their identity. At the same time, the Exo cargo was analyzed, and it was found that PRP-Exo contained TGF β 1, PDGFBB, VEGF and SDF-1. Since the main bioactive molecules in platelet pellet (PP), are encapsulated in the Exo [20], and released after activation, the surface markers of Exo and growth factors in the activated platelet pellet (APP) barely existed as compared with PRP-Exo (Fig. 1C).

Characterization of Exo-Gel

As previously reported by our team [33], the thermosensitive Gel was an ideal injectable carrier to deliver drugs, and the total polymer concentration of blank hydrogel was set to 22.9% (w/w), of which the concentration of Poloxamer 407 and 188 was fixed at 17.9% (w/w) and 5% (w/w) respectively. When Exo were mixed with Gel, Exo-Gel still was reversibly converted from a liquid polymer solution at room temperature into a hydrogel at 37 °C as blank gel, showing a thermoresponsiveness, which may highlight that the presence of Exo does not hamper Gel gelation process (Fig. 1D). The morphology of Exo loaded in Gel was examined by scanning electron microscopy (SEM) and the outline of round nanoparticles could be clearly observed (Fig. 1E). To study the use of thermosensitive Gel for sustained Exo delivery, 100 μl of Gel with 200 μg of Exo transferred to an insert of a transwell system containing medium in the bottom compartment at 25 and 37 °C (Fig. 1F), and conditioned medium was sampled at several time-points and quantified using the Bradford Protein Assay Kit (Fig. 1G). In the case of Exo-Gel, the vast majority of Exo released to the medium after 1 day at 25 °C. After increasing the temperature to 37 °C, Exo continually released from Gel to the medium, lasting for about 1 month. Additionally, NTA analysis showed that the particle size distribution of Exo released from Gel in the conditioned medium sampled at 2d was similar with initial PRP-Exo (Fig. 1H). Importantly, Exo have the ability to transfer their biological cargo, including

(See figure on next page.)

Fig. 4 Exo-Gel promoted proliferation and migration of chondrocytes in vitro. **A** In vitro investigate the effect of conditioned medium after Exo-Gel incubation for 1 week on proliferation and migration of chondrocytes by co-culture. **B** The cell viability of chondrocytes examined by CCK-8 analysis. Data are expressed as means \pm SEM (n = 6). * $p < 0.05$, Exo-Gel compared to Gel group. **C** Proliferation of chondrocytes was confirmed by EDU kit assay (bar = 100 μm). **D** Quantification of rate of EDU positive cells in **C** was performed. Data are expressed as means \pm SEM (n = 8). **E** Transwell assay to show a representative image of migrating chondrocytes (bar = 200 μm). **F** Quantitative analysis of migrating cells in **E**. Data are expressed as means \pm SEM (n = 6). **G** A representative image showing the migration ability of chondrocytes by the scratch test (bar = 500 μm). **H** Quantitative analysis of chondrocyte migration rate (**G**). Data are expressed as means \pm SEM (n = 6). * $p < 0.05$





Fig. 4 (See legend on previous page.)



proteins and RNA, between cells after Exo uptake by the recipient cell [34], which is key for biologically active of Exo. Therefore, to ensure that Exo maintain their integrity after release from Gel, we assessed Exo uptake by mouse bone marrow stromal cells (mBMSCs) and chondrocytes. Then, mBMSC phenotype was identified using morphological images (Additional file 1: Fig. S1A, B), flow cytometry (Additional file 1: Fig. S1C--F) and three-lineage differentiation (Additional file 1: Fig. 1SG--I). DiR-labeled incorporated Gel placed in a transwell insert and cocultured with mBMSCs and chondrocytes in the bottom well (Fig. 1I). After 48h, DiR-labeled Exo were visible in mBMSCs or chondrocytes cocultured with Gel (Fig. 1J). These results indicated that Gel matrix had the ability to sustain the release of Exo without characteristic change for a long period of time at the body temperature.

Exo-Gel promoted proliferation and migration of mBMSCs

BMSCs have the ability to differentiate into chondrocytes and are a well-known cell source for cartilage tissue engineering [35, 36]. Therefore, the key step is to stimulate the chemotaxis of a sufficient number of endogenous BMSCs to the injured site. SDF-1 is abundant in PRP [37], and the analysis of Exo protein content revealed a higher amount of SDF-1 as compared to APP (Fig. 1C). Binding to CXCR4 on BMSCs, SDF-1 can drive cell migration in tissue repair after injury [38, 39] or cartilage repair after osteoarthritis [40, 41]. It has also been shown to induce the migration of BMSCs to other locations, such as the brain [42] and heart [43]. Therefore, we believed that SDF-1 released by Exo induced endogenous BMSCs recruitment and promoted the repair of OA. Initially, we evaluated if Exo released from Exo-Gel after 1 week maintained their functional ability in targeted mBMSCs, mBMSCs were cultured in conditioned medium supplemented with Exo-Gel for a series of functional assays (Fig. 2A). The proliferation of cells was examined by CCK-8 analysis (Fig. 2B) and confirmed by EDU assay (Fig. 2C). The results revealed that conditioned medium after Exo-Gel incubation markedly increased proliferative capability of cells. Meanwhile, the conditioned medium could promote migration of mBMSCs evaluated using the transwell and scratch wound assays. These results showed that Exo released by Exo-Gel after incubation for

1 week in vitro still had biological activity and could promote the proliferation and migration of mBMSCs.

Exo-Gel promoted chondrogenic differentiation of mBMSCs

Previous study has showed a higher amount of growth factors in PRP-Exo [20], which play an important role in chondrogenic differentiation. Subsequently, Exo-Gel was cocultured with mBMSCs and chondrogenic differentiation at different time-points of induction culture was evaluated by RT-PCR (Fig. 3A). Our results indicated that mRNA expressions of type II Collagen (COL II), Aggrecan (ACAN), and SOX9 representing chondrogenic differentiation from the 7th day after coculture with Exo-Gel were significantly higher than those in blank Gel group (Fig. 3B). Alcian blue (AB) staining (Fig. 3C) and immunofluorescence staining (Fig. 3D) confirmed that cartilage clumps in Exo-Gel group on the 14th day of induced differentiation were more obvious. At the same time-point, the protein expressions of COL II, ACAN, and SOX9 were also showed a significant increase in Exo-Gel group as compared to Gel group (Fig. 3E, F).

As a key factor in the regulation of chondrogenic differentiation, TGF β isoforms, including TGF β 1, TGF β 2 and TGF β 3, activates Smad2/3, ERK1/2 and p38 signaling pathways during the process [44], which is consistent with our results (Fig. 4G, H). In this study, TGF β 3 was applied to induce chondrogenic differentiation, and our result confirmed that Exo contained a large amount of TGF β 1 protein (Fig. 1C). To verify whether Exo enhanced chondrogenic differentiation ability through the content of TGF β 1, TGF β 1 neutralizing antibody was administered in Exo-Gel and BMSCs co-culture system (Fig. 3G, H). After treatment with TGF β 1 (1 μ g/ml) neutralizing antibody, Smad2/3, ERK1/2 and p38 phosphorylation did not change significantly. As we expected, in Exo-Gel group, it could be observed that TGF β 1 neutralizing antibody significantly downregulated activation of Smad2/3, ERK1/2 and p38 signals and significantly inhibited the formation of cartilage (Fig. 3I, J). These results suggested that Exo increased chondrogenic differentiation ability of mBMSCs by releasing TGF β 1. Interestingly, after administration of TGF β 1 neutralizing antibody in Exo-gel group and Gel group, activation level of ERK1/2 and

(See figure on next page.)

Fig. 6 Exo-Gel suppressed IL-1 β -triggered chondrocyte degeneration and enhanced anabolism in vitro. **A** Immunofluorescent assay to detect the expression of COL II (Gree), COL X (Green), and MMP13 (Green) in chondrocytes in different treatment groups, DAPI (blue) staining for cell nuclei (bar = 200 μ m). **B** Quantification of COL II, COL X, and MMP13 fluorescence intensity in **A**. Data are expressed as means \pm SEM (n = 6). **C** Representative Western blots of COL II, COL X, and MMP13 expression in chondrocytes in different groups. **D** Quantification of COL II, COL X, and MMP13 protein expression in chondrocytes in **C**. GAPDH was used as loading control. Data are expressed as means \pm SEM (n = 3). **E** Representative Western blot showing the levels of total protein and phosphorylated protein for the indicated molecules (p65 and STAT3) in chondrocytes in different treatment groups. **F** Quantification of protein expression and the level of signaling activation in **E**. GAPDH was used as loading control. Data are expressed as means \pm SEM (n = 3) *p < 0.05





Fig. 6 (See legend on previous page.)



p38 signal in the former was still higher than that in the latter (Fig. 3G, H), which hinted that other growth factor, such as fibroblast growth factor (FGF) [45–47] in PRP-Exo released from Exo-Gel assisted regulation of chondrogenic differentiation.

Exo-Gel promoted proliferation and migration of chondrocytes


In order to further determine the potential therapeutic effect of Exo-Gel on cartilage repair, we evaluated the growth of chondrocytes by in vitro CCK8 test and EDU analysis (Fig. 4A–D). The effect of Exo-Gel on the increasing proliferation of chondrocytes is similar to that of mBMSCs. Transwell and scratch tests showed that Exo-containing culture after Exo-Gel incubation could markedly enhance the migration ability of chondrocytes (Fig. 4E–H). In general, these findings indicated that compared with PBS and Gel treatment, Exo-Gel could promote the proliferation and migration to a greater extent in vitro.

Exo-Gel inhibited IL-1β-induced chondrocyte apoptosis and degeneration

Among the cytokines believed to play a role in progression of OA, IL-1β and TNF-α are known to be the predominant mediators of inflammation [48–50], which aggravate the catabolic imbalance in OA cartilage and exacerbate degradation and alterations of articular


cartilage matrix. Therefore, we evaluated the protective effect of conditioned medium after incubation with Exo-Gel for 1 week on chondrocytes in the presence of IL-1β (10 ng/ml) in vitro. Firstly, we observed the influence of Exo-Gel on the cell apoptosis of chondrocytes by TUNEL staining and Annexin V-FITC/PI flow cytometry (Fig. 5A–D). Conditioned medium after Exo-Gel incubation remarkably decreased the rate of apoptosis of chondrocytes triggered by IL-1β. Western blotting (Fig. 5E, F) demonstrated that the expression of cleaved-caspase3 (Cleaved-Cas3) protein in chondrocytes in response to IL-1β treatment was higher than that in the cells cocultured with conditioned medium from Exo-Gel incubation. Meanwhile, the Bcl-2/Bax ratio calculated from Western blotting result was significantly increased in the IL-1β + Exo-Gel group. These results indicated that Exo-Gel could attenuate inflammatory apoptosis during cartilage degeneration.

Furthermore, inflammatory cytokines affect the physiological metabolism of chondrocytes by activating catabolic pathways, and promote the imbalance of catabolic and anabolic balance. Matrix metalloproteinase (MMP) 13 is a catabolism-related factor and widely known as a proteolytic enzyme, that can cause the degradation of extracellular matrix (ECM) components, especially COL II and ACAN [51], which is strongly related to the pathological process of OA. Moreover, transcription factor nuclear factor kappa B (NF-κB), activated by IL-1β in



chondrocytes, shuts down almost all anabolic pathways, including the production of COL II and ACAN [49, 52, 53]. Single cell RNA-seq studies in OA, have shown that chondrocytes undergo phenotypic changes and become hypertrophy, leading to cartilage damage and aggravating diseases [54–56]. In addition, hypertrophic chondrocytes produce alkaline phosphatase, leading to matrix calcification and increase the expression of hypertrophic-related gene, type X Collagen (COL X) [57]. MMP13 as other

main characteristic is also upregulated in hypertrophic chondrocytes [55, 56]. Then, we analyzed the protein expression of COL II, COL X and MMP13 in IL-1 β -stimulated chondrocytes cocultured with conditioned medium after Gel or Exo-Gel incubation for 24 h. Immunofluorescence analysis (Fig. 6A–F) and Western blotting result (Fig. 6G, H) both showed that IL-1 β remarkably diminished expression of COL II and increased the levels of COL X and MMP13. Interestingly, treatment with



conditioned medium from the administration of Exo-Gel, but not Gel, reversed the effects of IL-1β on COL II, COL X and MMP13.

It is now well accepted that pro-inflammatory cytokines, which activate the JAK/STAT pathway [58–62] as well as the NF-κB pathway both modulating the

expression of COL II, COL X and MMP13 are critically involved in the development of OA [63–65]. The further *in vitro* results showed that conditioned medium from the administration of Exo-Gel decreased phosphorylation of p65 as a member of NF- κ B family and STAT3 in chondrocytes treated with IL-1 β (Fig. 6I, J). In summary, the above results indicate that Exo-Gel could attenuate IL-1 β -triggered apoptosis and degeneration of chondrocytes through inhibiting NF- κ B and STAT signaling pathway.

Exo-Gel boosted retention of Exo in limbs

According to those previously described [11–13], ankle-subtalar joint complex instability was established by transecting ATFL/CFL, to induce posttraumatic STOA. The thermoresponsive Gel, due to its viscosity and hardness, provides a natural matrix barrier to lock Exo and prevents its rapid loss. *In vitro*, we had demonstrated that Exo-Gel served as a temporary repository for the continuous release of Exo without change biological characteristics. The DiR-labeled Exo was intra-articularly injected with or without Gel *in situ* to subtalar joint, and then the retention was analyzed using IVIS imaging system *in vivo* (Fig. 7A). The results at 3, 7, 14, and 28 d after injection revealed that compared with the joints treated with Exo alone, Exo-Gel-treated joint had a stronger fluorescent signal (representing DiR-labeled Exo) (Fig. 7B, C), indicating that Gel enhanced Exo retention in the injured joint. As we had discovered, the main disadvantage of direct injection of Exo was quick clearance from the joints, which could cause the drug concentration reduction at the site of action and limited uptake of the agents by the targeted cells [66]. Clinically, more frequent injections can result in infection, inflammation and decreased compliance. Thus, in this study, we only evaluated the therapeutic effect of Exo-Gel on chronic STOA *in vivo*.

Exo-Gel alleviated STOA

At 8 weeks, safranin-O, HE, toluidine blue (TB) and AB staining were used to show the integrity of articular cartilage at mouse ankle-subtalar OA model by resection of lateral ligaments/tendons (Fig. 8A; Additional file 1: Fig. S2). Notably, in contrast to sham group, subtalar joint was degenerated at 8 weeks after the surgery while tibiotalar joint was less degenerated. In subtalar joint, lateral surface of the calcaneus was mainly affected, and severe cartilage degeneration there was observed, which is consistent with previous literature reports [13]. The cartilage in Exo-Gel group showed mild degeneration, and normal morphology and distribution of chondrocytes, with more appearance to normal cartilage than the control group or Gel group, which manifested remarkable thinning of articular cartilage, and atypical distribution of cartilage

cells (Fig. 8A, B). Due to quick clearance of Exo from the joints (Fig. 7), the serious abrasion of the cartilage surface of talocrural joint could still be observed after Exo-PBS injected directly as expected (Additional file 1: Fig. S2). On the basis of the Histological grading, OARSI and Mankin histological score of subtalar joint (Fig. 8C–E) in operated and sham limbs, for quantifying the extent of cartilage injury, the data showed that Exo-Gel exhibited a more evidently protective influence on cartilage after ankle-subtalar joint complex instability, and delay occurrence of STOA.

Exo-Gel inhibited degeneration of cartilage of subtalar joint

Finally, we sequentially analyzed biological characteristics of chondrocytes of the ankle during the development of OA at 4 weeks postinjury [13]. TUNEL positive cells increased in control group, indicating that chondrocyte apoptosis was induced by excessive mechanical loading in the earlier stage at 4 weeks (Fig. 9A, D). In contrast to Gel, Exo-Gel reduced apoptosis of chondrocytes. Meanwhile, immunohistochemistry showed that hypertrophic chondrocytes appear in abundance, and proliferation ability of chondrocytes decreased in OA model (Fig. 9B, C, E, F). However, Exo-Gel reversed the biological characteristics of chondrocytes, including inhibiting hypertrophy and increasing proliferation in the OA model. These data indicate that attenuation of chondrocyte apoptosis and degeneration after the treatment with Exo-Gel inhibited progression of STOA.

Discussion

Thermosensitive Gel with the good biocompatibility, as a polymer chain network, has been reported to be used as sustained release carrier of monosialoganglioside (GM1) [33]. In this study, we provided evidence that the incorporation of Exo did not affect the physical properties of thermosensitive Gel, the temperature-induced liquid-gel phase transition. Then, we found that Exo-Gel *in vitro* could sustain a slow-release of Exo, and did not affect the biological activity of Exo, which could provide a prolonged localized release of Exo. *In vivo*, our results as well highlighted that the retention of PRP-Exo in the ankle was improved by this Gel, which temporarily stored Exo and prevented fast diffusion of Exo out of the joint. These evidences provide a novel strategy of cell-free therapy in which the protection of cartilage after joint instability is reinforced from the sustained release of therapeutic PRP-Exo.

Recently, it has been suggested PRP activity might also be due to the efficient intercellular communication of bioactive molecules, mediated by nanosized vesicles, identified as Exo [20]. Besides, a high expression of marker

proteins of Exo, such as CD9, CD63, and CD81 [22, 23, 67], these growth factors, including TGF β 1, PDGFBB, VEGF, and SDF-1 identified as widespread in PRP [14], could also exist encapsulated within Exo. The growth factors have a positive regulation effect on the proliferation and migration of mBMSCs and chondrocytes [24, 33, 49], and PRP-Exo have a possible physiological role as a means of delivering these growth factors across the extracellular space in tissue regeneration [68–70]. Our results verified that Exo released from Exo-Gel has the same effects with growth factors, besides that they could be taken up by cells as well as normal Exo, which prompted that Gel did not affect the biological function of Exo and its contents. Furthermore, our data indicated that inhibition of TGF β 1 by its neutralizing antibody could suppress Smad2/3, ERK1/2, and p38 signaling pathways, as considered to be the key in the regulation of chondrogenic differentiation of BMSCs [44], leading to the weakened ability of Exo-induced chondrogenic differentiation. We also found that after neutralizing TGF β 1, ERK1/2 and p38 activation level in mBMSCs treated with Exo was still higher than that in Gel group, suggesting that other growth factors are involved in the regulation of chondrogenic differentiation [45–47].

A review conducted by Andia and Maffulli [49] confirmed that growth factors present in PRP might be responsible, at least in part, for the antiinflammatory effects, partially attributable to reduced NF- κ B signaling. Corroborating these findings, PDGFBB is showed to inhibit I κ B kinase α (IKK α), thereby suppressing activation of NF- κ B and transcription of its downstream targets involved in inflammation, cartilage degradation or chondrocyte apoptosis and reversing the antianabolic effects of IL-1 β [71]. Moreover, PRP releasate completely reversed the IL-1 β -induced inflammatory response of chondrocytes isolated from patients with OA, contribute to the decrease in NF- κ B activation [72], and the recovered synthesis of COL II and ACAN [72, 73]. TGF- β has been reported to prevent hypertrophy via Smad2/3 signaling, through upregulating the expression of SOX9 and downregulating the expression of runt-related transcription factor (RUNX)2 [54]. As two main chondrocyte phenotype-determining transcriptional regulators, they are reversely regulated by pro-inflammatory cytokines such as IL-1 β and TNF- α [74]. Previous studies have shown that proinflammatory cytokines can also activate the STAT3 signaling pathway to induce chondrocyte damage [58–62]. Although there are few studies on the anti-inflammatory effects of PRP-Exo on chondrocytes, considering that the contents of Exo are similar to those in PRP, we believe that Exo have strong anti-inflammatory effects and can inhibit inflammation-induced

chondrocyte apoptosis and degeneration. Our data showed that Exo could simultaneously inhibit the activation of IL-1 β -induced-NF- κ B and -STAT3 in chondrocytes to play a protective effect.

The animal model of ankle sprain was first reported in 2008 [75]. Based on that study, in 2015 Chang et al. [13] elaborated the cytohistological change in the cartilage on talocrural joint and subtalar joint after different ankle ligament resection in mice. It was confirmed that the lateral ligamentectomy of ATFL and CFL only induced the occurrence of subtalar OA, and had almost no effect on talocrural joint. In 2021, Liu et al. [76] believed that the resection of the lateral ligaments would not only cause the degeneration of subtalar joint, but also affect the development of the medial talocrural OA. Although there is some controversy over whether the lateral ligament resection model can induce the degeneration of talocrural joint, it is certain that the lateral ligament resection can provide a reliable animal model of STOA. In this study, the site of ankle OA induced by lateral ligament resection model were similar to those demonstrated by Chang et al. [13] with a high probability at 8 weeks, that is, subtalar joint was affected, but not talocrural joint. However, due to the late start of the research on STOA model, compared with the knee OA, its occurrence mechanism and interventions is still rarely reported at present. Our data showed that in the process of STOA, the chondrocytes of cartilage surface, especially on the side of the calcaneus, undergone apoptosis and hypertrophy, and their proliferation ability was significantly weakened, which is similar to the changes in chondrocyte biological behavior in the process of knee OA [54–57]. However, Exo-Gel inhibited chondrocyte apoptosis and hypertrophy and promoted their proliferation, leading to alleviation of STOA. SDF-1 has been confirmed to be able to recruit endogenous MSCs to the injured area and participate in OA repair [40, 41]. Since these factors including SDF-1 and TGF β 1 are abundant in Exo, the induction of stem cell homing and chondrogenic differentiation may be another mechanism of cartilage repair.

In this study, PRP-derived Exo were incorporated in thermosensitive Gel as a sustained delivery system. Our study demonstrated that PRP-Exo had positive regulation of mBMSCs function and played a protective role against IL-1 β -induced apoptosis and degeneration of chondrocytes *in vivo*. Application of this system allowed retention of Exo in the ankle compared to Exo only injection, and consequently maintained the local concentration of Exo. Together, Exo-Gel have effective effects on suppressing cartilage degeneration and development of STOA.

Abbreviations

Exo: Exosomes; PRP: Platelet-rich plasma; PRP-Exo: Platelet-rich plasma-derived exosomes; Hydrogel: Gel; Exo-Gel: Platelet-rich plasma-derived exosomes incorporated Hydrogel; OA: Osteoarthritis; STOA: Subtalar osteoarthritis; ATFL: Anterior talofibular ligament; CFL: Calcaneal fibular ligament; mBMSCs: Mouse bone mesenchymal stem cells; TGF β 1: Transforming growth factor β 1; PDGFBB: Platelet derived growth factor BB; VEGF: Vascular endothelial growth factor; SDF-1: Stromal cell derived factor-1; COL II: type II Collagen; COL X: type X Collagen; ACAN: Aggrecan; NF- κ B: Transcription factor nuclear factor kappa B; MMP13: Matrix metalloproteinase 13; APP: Activated platelet pellet; TEM: transmission electron microscopy; SEM: Scanning electron microscopy; NTA: Nanosight tracking analysis; AB: Alcian blue; TB: Toluidine blue (TB).

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12951-022-01245-8>.

Additional file 1: Figure S1. Identify of mBMSCs. **Figure S2.** Exo-PBS did not prevent the progress of STOA.

Acknowledgements

The authors in this study would like to thank Prof. Dongfei Liu from State Key Laboratory of Natural Medicines, Department of Pharmaceutical Science, China Pharmaceutical University, for help and guidance in hydrogel preparation.

Authors' contributions

GY, JC, QL, SZ, and YZ designed research; JC, YZ, XW, DQ, and PG analyzed data; JC, YZ, XW, DQ, PG, DQ, TQ, TJ, JY, TX, YH, QW, ZZ, TB, XZ, HL, ZY, and JF performed research; JC, YZ, and XW wrote the paper. All authors read and approved the final manuscript.

Funding

The authors acknowledge financial support from the National Natural Science Foundation of China (Grant Nos. 81902211, 82030069, 81772351, and 8151001184), the Jiangsu Natural Science Foundation (Grant Nos. BK20191061), and the Jiangsu Committee of Science and Technology–Social Development Plan (Grant Nos. BE2017755).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

All experimental procedures were conducted in conformity with institutional guidelines for the care and use of laboratory animals and protocols, which were approved by the Animal Care and Use Committee of Affiliated Drum Tower Hospital, Medical School of Nanjing University (No. YKK1760). C57/B6 male mice were provided by Gempharmatech.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflict of interests.

Author details

¹Department of Orthopedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu, China. ²Department of Orthopedics, The Fourth Medical Center, Chinese PLA General Hospital, Haidian, Beijing 100036, China.

Received: 31 October 2021 Accepted: 4 January 2022

Published online: 29 January 2022

References

- Fernandez WG, Yard EE, Comstock RD. Epidemiology of lower extremity injuries among U.S. high school athletes. *Acad Emerg Med*. 2007;14(7):641–5.
- Gimigliano F, Resmini G, Moretti A, Aulicino M, Gargiulo F, Gimigliano A, Liguori S, Paoletta M, Iolascon G. Epidemiology of musculoskeletal injuries in adult athletes: a scoping review. *Medicina (Kaunas)*. 2021;57(10):1118. <https://doi.org/10.3390/medicina57101118>.
- Herzog MM, Kerr ZY, Marshall SW, Wikstrom EA. Epidemiology of ankle sprains and chronic ankle instability. *J Athlete Train*. 2019;54(6):603–10.
- Medina McKeon JM, Hoch MC. The ankle-joint complex: a kinesiology approach to lateral ankle sprains. *J Athlete Train*. 2019;54(6):589–602.
- Hirose K, Murakami G, Minowa T, Kura H, Yamashita T. Lateral ligament injury of the ankle and associated articular cartilage degeneration in the talocrural joint: anatomic study using elderly cadavers. *J Orthop Sci*. 2004;9(1):37–43.
- Valderrabano V, Hintermann B, Horisberger M, Fung TS. Ligamentous posttraumatic ankle osteoarthritis. *Am J Sports Med*. 2006;34(4):612–20.
- Gribble PA, Bleakley CM, Caulfield BM, Docherty CL, Fourchet F, Fong DT, Hertel J, Hiller CE, Kaminski TW, McKeon PO, et al. Evidence review for the 2016 International Ankle Consortium consensus statement on the prevalence, impact and long-term consequences of lateral ankle sprains. *Br J Sports Med*. 2016;50(24):1496–505.
- Mittlmeier T, Rammelt S. Update on subtalar joint instability. *Foot Ankle Clin*. 2018;23(3):397–413.
- Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, Flannery CR, Peluso D, Kanki K, Yang Z, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. *Nature*. 2005;434(7033):644–8.
- Kamekura S, Hoshi K, Shimoaka T, Chung U, Chikuda H, Yamada T, Uchida M, Ogata N, Seichi A, Nakamura K, Kawaguchi H. Osteoarthritis development in novel experimental mouse models induced by knee joint instability. *Osteoarthritis Cartil*. 2005;13(7):632–41.
- Wikstrom EA, Hubbard-Turner T, Woods S, Guderian S, Turner MJ. Developing a mouse model of chronic ankle instability. *Med Sci Sports Exerc*. 2015;47(4):866–72.
- Hubbard-Turner T, Wikstrom EA, Guderian S, Turner MJ. Acute ankle sprain in a mouse model. *Med Sci Sports Exerc*. 2013;45(8):1623–8.
- Chang SH, Yasui T, Taketomi S, Matsumoto T, Kim-Kaneyama JR, Omiya T, Hosaka Y, Inui H, Omata Y, Yamagami R, et al. Comparison of mouse and human ankles and establishment of mouse ankle osteoarthritis models by surgically-induced instability. *Osteoarthritis Cartil*. 2016;24(4):688–97.
- Dhillon RS, Schwarz EM, Maloney MD. Platelet-rich plasma therapy - future or trend? *Arthritis Res Ther*. 2012;14(4):219.
- Kanchanatawan W, Arirachakaran A, Chaijenkij K, Prasathaporn N, Boonard M, Piyapittayanun P, Kongtharvonskul J. Short-term outcomes of platelet-rich plasma injection for treatment of osteoarthritis of the knee. *Knee Surg Sports Traumatol Arthrosc*. 2016;24(5):1665–77.
- Dorio M, Pereira RMR, Luz AGB, Deveza LA, de Oliveira RM, Fuller R. Efficacy of platelet-rich plasma and plasma for symptomatic treatment of knee osteoarthritis: a double-blinded placebo-controlled randomized clinical trial. *BMC Musculoskelet Disord*. 2021;22(1):822.
- Khoshbin A, Leroux T, Wasserstein D, Marks P, Theodoropoulos J, Ogilvie-Harris D, Gandhi R, Takhar K, Lum G, Chahal J. The efficacy of platelet-rich plasma in the treatment of symptomatic knee osteoarthritis: a systematic review with quantitative synthesis. *Arthroscopy*. 2013;29(12):2037–48.
- Fukawa T, Yamaguchi S, Akatsu Y, Yamamoto Y, Akagi R, Sasho T. Safety and Efficacy of Intra-articular Injection of Platelet-Rich Plasma in Patients With Ankle Osteoarthritis. *Foot Ankle Int*. 2017;38(6):596–604.
- Repetto I, Biti B, Cerruti P, Trentini R, Felli L. Conservative Treatment of Ankle Osteoarthritis: Can Platelet-Rich Plasma Effectively Postpone Surgery? *J Foot Ankle Surg*. 2017;56(2):362–5.
- Torreggiani E, Perut F, Roncuzzi L, Zini N, Baglio SR, Baldini N. Exosomes: novel effectors of human platelet lysate activity. *Eur Cell Mater*. 2014;28:137–51. discussion 151.
- Montecalvo A, Larregina AT, Morelli AE. Methods of analysis of dendritic cell-derived exosome-shuttle microRNA and its horizontal propagation between dendritic cells. *Methods Mol Biol*. 2013;1024:19–40.

22. Guo SC, Tao SC, Yin WJ, Qi X, Yuan T, Zhang CQ. Exosomes derived from platelet-rich plasma promote the re-epithelization of chronic cutaneous wounds via activation of YAP in a diabetic rat model. *Theranostics*. 2017;7(1):81–96.
23. Tao SC, Yuan T, Rui BY, Zhu ZZ, Guo SC, Zhang CQ. Exosomes derived from human platelet-rich plasma prevent apoptosis induced by glucocorticoid-associated endoplasmic reticulum stress in rat osteonecrosis of the femoral head via the Akt/Bad/Bcl-2 signal pathway. *Theranostics*. 2017;7(3):733–50.
24. Wu JP, Piao YX, Liu QY, Yang XY. Platelet-rich plasma-derived extracellular vesicles: a superior alternative in regenerative medicine? *Cell Prolif*. 2021; 54(12):e13123. <https://doi.org/10.1111/cpr.13123>.
25. Ridder K, Keller S, Dams M, Rupp AK, Schlaudraff J, Turco DD, Starmann J, Macas J, Karpova D, Devraj K, Depboylu G, Landfried B, Arnold B, Plate KH, Höglinger G, Sültmann H, Altevogt P, Momma S. Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation. *PLoS Biol*. 2014;12(6):e1001874.
26. Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. *Nat Rev Immunol*. 2014;14(3):195–208.
27. Mol EA, Lei Z, Roefs MT, Bakker MH, Goumans MJ, Doevendans PA, Dankers PYW, Vader P, Sluijter JPG. Injectable supramolecular ureidopyrimidinone hydrogels provide sustained release of extracellular vesicle therapeutics. *Adv Healthc Mater*. 2019;8(20):e1900847.
28. Lv K, Li Q, Zhang L, Wang Y, Zhong Z, Zhao J, Lin X, Wang J, Zhu K, Xiao C, et al. Incorporation of small extracellular vesicles in sodium alginate hydrogel as a novel therapeutic strategy for myocardial infarction. *Theranostics*. 2019;9(24):7403–16.
29. Nikraves N, Davies OG, Azoidis I, Moakes RJA, Marani L, Turner M, Kearney CJ, Eisenstein NM, Grover LM, Cox SC. Physical structuring of injectable polymeric systems to controllably deliver nanosized extracellular vesicles. *Adv Healthc Mater*. 2019;8(9):e1801604.
30. Pena B, Laughter M, Jett S, Rowland TJ, Taylor MRG, Mestroni L, Park D. Injectable hydrogels for cardiac tissue engineering. *Macromol Biosci*. 2018;18(6):e1800079.
31. Moghimi SM, Hunter AC. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. *Trends Biotechnol*. 2000;18(10):412–20.
32. Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. *Pharm Res*. 2006;23(12):2709–28.
33. Liu D, Jiang T, Cai W, Chen J, Zhang H, Hietala S, Santos HA, Yin G, Fan J. An in situ gelling drug delivery system for improved recovery after spinal cord injury. *Adv Healthc Mater*. 2016;5(12):1513–21.
34. Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. *J Extracell Vesicles*. 2014;3.
35. Lee WY, Wang B. Cartilage repair by mesenchymal stem cells: clinical trial update and perspectives. *J Orthop Translat*. 2017;9:76–88.
36. Spinal Cord Injury (SCI). 2016 Facts and figures at a glance. *J Spinal Cord Med*. 2016;39(4):493–4.
37. Fernandez-Moure JS, Van Eps JL, Scherba JC, Yazdi IK, Robbins A, Cabrera F, Vatsaas C, Moreno M, Weiner BK, Tasciotti E. Platelet-rich plasma enhances mechanical strength of strattice in rat model of ventral hernia repair. *J Tissue Eng Regen Med*. 2021;15(7):634–47.
38. Spinal cord injury facts and figures at a glance. *J Spinal Cord Med*. 2014;37(5):659–660.
39. Li J, Chen H, Zhang D, Xie J, Zhou X. The role of stromal cell-derived factor 1 on cartilage development and disease. *Osteoarthritis Cartil*. 2021;29(3):313–22.
40. Xiang X, Liu H, Wang L, Zhu B, Ma L, Du F, Li L, Qiu L. Ultrasound combined with SDF-1 α chemotactic microbubbles promotes stem cell homing in an osteoarthritis model. *J Cell Mol Med*. 2020;24(18):10816–29.
41. Fernandez-Pernas P, Rodriguez-Lesende I, de la Fuente A, Mateos J, Fuentes I, De Toro J, Blanco FJ, Arufe MC. CD105⁺-mesenchymal stem cells migrate into osteoarthritis joint: an animal model. *PLoS One*. 2017;12(11):e0188072.
42. Hasegawa S, Kitoh H, Ohkawara B, Mishima K, Matsushita M, Masuda A, Ishiguro N, Ohno K. Tranilast stimulates endochondral ossification by upregulating SOX9 and RUNX2 promoters. *Biochem Biophys Res Commun*. 2016;470(2):356–61.
43. Spinal Cord Injury (SCI). Facts and figures at a glance. *J Spinal Cord Med*. 2016;39(2):243–4.
44. Li J, Zhao Z, Liu J, Huang N, Long D, Wang J, Li X, Liu Y. MEK/ERK and p38 MAPK regulate chondrogenesis of rat bone marrow mesenchymal stem cells through delicate interaction with TGF- β 1/Smads pathway. *Cell Prolif*. 2010;43(4):333–43.
45. Narcisi R, Cleary MA, Brama PA, Hoogduijn MJ, Tuysuz N, ten Berge D, van Osch GJ. Long-term expansion, enhanced chondrogenic potential, and suppression of endochondral ossification of adult human MSCs via WNT signaling modulation. *Stem Cell Rep*. 2015;4(3):459–72.
46. Correa D, Somoza RA, Lin P, Greenberg S, Rom E, Duesler L, Welter JF, Yayon A, Caplan AI. Sequential exposure to fibroblast growth factors (FGF) 2, 9 and 18 enhances hMSC chondrogenic differentiation. *Osteoarthritis Cartil*. 2015;23(3):443–53.
47. Szwedowski D, Szczepanek J, Paczesny L, Zabrzynski J, Gagat M, Mobasheri A, Jeka S. The effect of platelet-rich plasma on the intra-articular microenvironment in knee osteoarthritis. *Int J Mol Sci*. 2021;22(11).
48. Kobayashi M, Squires GR, Mousa A, Tanzer M, Zukor DJ, Antoniou J, Feige U, Poole AR. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. *Arthritis Rheum*. 2005;52(1):128–35.
49. Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. *Nat Rev Rheumatol*. 2013;9(12):721–30.
50. Umlauf D, Frank S, Pap T, Bertrand J. Cartilage biology, pathology, and repair. *Cell Mol Life Sci*. 2010;67(24):4197–211.
51. Troeberg L, Nagase H. Proteases involved in cartilage matrix degradation in osteoarthritis. *Biochim Biophys Acta*. 2012;1824(1):133–45.
52. Lauer JC, Selig M, Hart ML, Kurz B, Rolauffs B. Articular chondrocyte phenotype regulation through the cytoskeleton and the signaling processes that originate from or converge on the cytoskeleton: towards a novel understanding of the intersection between actin dynamics and chondrogenic function. *Int J Mol Sci*. 2021;22(6).
53. Liu CF, Angelozzi M, Haseeb A, Lefebvre V. SOX9 is dispensable for the initiation of epigenetic remodeling and the activation of marker genes at the onset of chondrogenesis. *Development*. 2018;145(14).
54. Ferrao Blanco MN, Domenech Garcia H, Legeai-Mallet L, van Osch G. Tyrosine kinases regulate chondrocyte hypertrophy: promising drug targets for Osteoarthritis. *Osteoarthritis Cartil*. 2021;29(10):1389–98.
55. Ji Q, Zheng Y, Zhang G, Hu Y, Fan X, Hou Y, Wen L, Li L, Xu Y, Wang Y, Tang F. Single-cell RNA-seq analysis reveals the progression of human osteoarthritis. *Ann Rheum Dis*. 2019;78(1):100–10.
56. Chou CH, Jain V, Gibson J, Attarian DE, Haraden CA, Yohn CB, Laberge RM, Gregory S, Kraus VB. Synovial cell cross-talk with cartilage plays a major role in the pathogenesis of osteoarthritis. *Sci Rep*. 2020;10(1):10868.
57. Yan D, Chen D, Cool SM, van Wijnen AJ, Mikecz K, Murphy G, Im HJ. Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes. *Arthritis Res Ther*. 2011;13(4):R130.
58. Mevel E, Shutter JA, Ding X, Mattingly BT, Williams JN, Li Y, Huls A, Kambrath AV, Trippel SB, Wagner D, et al. Systemic inhibition or global deletion of CaMKK2 protects against post-traumatic osteoarthritis. *Osteoarthritis Cartil*. 2022; 30(1):124–36.
59. Adan N, Guzman-Morales J, Ledesma-Colunga MG, Perales-Canales SI, Quintanar-Stephano A, Lopez-Barrera F, Mendez I, Moreno-Carranza B, Triebel J, Binart N, et al. Prolactin promotes cartilage survival and attenuates inflammation in inflammatory arthritis. *J Clin Invest*. 2013;123(9):3902–13.
60. Minashima T, Zhang Y, Lee Y, Kirsch T. Lithium protects against cartilage degradation in osteoarthritis. *Arthritis Rheumatol*. 2014;66(5):1228–36.
61. Kihara S, Hayashi S, Hashimoto S, Kanzaki N, Takayama K, Matsumoto T, Chinzei N, Iwasa K, Haneda M, Takeuchi K, et al. Cyclin-dependent kinase inhibitor-1-deficient mice are susceptible to osteoarthritis associated with enhanced inflammation. *J Bone Miner Res*. 2017;32(5):991–1001.
62. Yao ZZ, Hu AX, Liu XS. DUSP19 regulates IL-1 β -induced apoptosis and MMPs expression in rat chondrocytes through JAK2/STAT3 signaling pathway. *Biomed Pharmacother*. 2017;96:1209–15.
63. Liang T, Chen T, Qiu J, Gao W, Qiu X, Zhu Y, Wang X, Chen Y, Zhou H, Deng Z, et al. Inhibition of nuclear receptor ROR α attenuates cartilage damage in osteoarthritis by upregulating IL-6/STAT3 pathway. *Cell Death Dis*. 2021;12(10):886.

64. Zhan J, Yan Z, Kong X, Liu J, Lin Z, Qi W, Wu Y, Lin J, Pan X, Xue X. Lycopene inhibits IL-1beta-induced inflammation in mouse chondrocytes and mediates murine osteoarthritis. *J Cell Mol Med*. 2021;25(7):3573–84.
65. Lu W, Ding Z, Liu F, Shan W, Cheng C, Xu J, He W, Huang W, Ma J, Yin Z. Dopamine delays articular cartilage degradation in osteoarthritis by negative regulation of the NF-kappaB and JAK2/STAT3 signaling pathways. *Biomed Pharmacother*. 2019;119:109419.
66. Younas A, Gu H, Zhao Y, Zhang N. Novel approaches of the nanotechnology-based drug delivery systems for knee joint injuries: a review. *Int J Pharm*. 2021;608:121051.
67. Tao SC, Guo SC, Zhang CQ. Platelet-derived extracellular vesicles: an emerging therapeutic approach. *Int J Biol Sci*. 2017;13(7):828–34.
68. Melki I, Tessandier N, Zufferey A, Boilard E. Platelet microvesicles in health and disease. *Platelets*. 2017;28(3):214–21.
69. Johnson J, Wu YW, Blyth C, Lichtfuss G, Goubran H, Burnouf T. Prospective therapeutic applications of platelet extracellular vesicles. *Trends Biotechnol*. 2021;39(6):598–612.
70. Boilard E. Extracellular vesicles and their content in bioactive lipid mediators: more than a sack of microRNA. *J Lipid Res*. 2018;59(11):2037–46.
71. Montaseri A, Busch F, Mobasheri A, Buhrmann C, Aldinger C, Rad JS, Shakibaei M. IGF-1 and PDGF-bb suppress IL-1beta-induced cartilage degradation through down-regulation of NF-kappaB signaling: involvement of Src/PI-3K/AKT pathway. *PLoS One*. 2011;6(12):e28663.
72. van Buul GM, Koevoet WL, Kops N, Bos PK, Verhaar JA, Weinans H, Bernsen MR, van Osch GJ. Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes. *Am J Sports Med*. 2011;39(11):2362–70.
73. Huang W, Begum R, Barber T, Ibba V, Tee NC, Hussain M, Arastoo M, Yang Q, Robson LG, Lesage S, et al. Regenerative potential of silk conduits in repair of peripheral nerve injury in adult rats. *Biomaterials*. 2012;33(1):59–71.
74. Ferrao Blanco MN, Bastiaansen-Jenniskens YM, Chambers MG, Pitsillides AA, Narcisi R, van Osch GJVM. Effect of inflammatory signaling on human articular chondrocyte hypertrophy: potential involvement of tissue repair macrophages. *Cartilage*. 2021;13(2_suppl):168S-74S. <https://doi.org/10.1177/19476035211021907>.
75. Kim HY, Wang J, Chung K, Chung JM. A surgical ankle sprain pain model in the rat: effects of morphine and indomethacin. *Neurosci Lett*. 2008;442(2):161–4.
76. Liu P, Chen K, Wang S, Hua C, Zhang H, Yu J. A mouse model of ankle-subtalar joint complex instability induced post-traumatic osteoarthritis. *J Orthop Surg Res*. 2021;16(1):541.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

